Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lerapolturev

Phase 2Small molecule

IIstari Oncology, Inc.

1

Indications

5

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Supratentorial GlioblastomaRecruiting

Recurrent Supratentorial GlioblastomaPhase 2

Recruiting

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Recurrent Supratentorial Glioblastoma

NCT06177964

Clinical

Trials by Indication[1]

Melanoma1 trial

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Completed·IIstari Oncology, Inc.·Phase 2·NCT04577807·27 enrolled

Malignant Glioma1 trial

Lerapolturev in Recurrent Malignant Glioma

Completed·IIstari Oncology, Inc.·Phase 2·NCT02986178·121 enrolled

Glioblastoma1 trial

LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma

Completed·IIstari Oncology, Inc.·Phase 2·NCT04479241·25 enrolled

Efficacy1 trial

LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors

Terminated·IIstari Oncology, Inc.·Phase 1/2·NCT04690699·4 enrolled

Recurrent Supratentorial Glioblastoma1 trial

Randomized Phase 2 Clinical Trial of Repeated Intratumoral and Cervical Perilymphatic Lerapolturev Injections Versus Lomustine in Recurrent Glioblastoma (GBM)

Recruiting·DDarell Bigner·Phase 2·NCT06177964·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Lerapolturev. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lerapolturev compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lerapolturev. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Istari Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIstari Oncology, Inc.

Related News